Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer

Image: Roche secures FDA approval for Kadcyla as adjuvant treatment of HER2+ early breast cancer. Photo: courtesy of F. Hoffmann-La Roche Ltd.